Skip to Content
 

News: Featured Clinical Trials

Combination therapy improves small-cell lung cancer survival

Friday, October 26th, 2018

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

Study to test combination therapy for breast cancer

Friday, October 27th, 2017

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Horn to lead lung cancer combination therapy trial

Sunday, April 2nd, 2017

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer. The Phase 1/2 trial will test the drugs […]

VICC trial putting lung cancer therapy to the test

Thursday, October 20th, 2016

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]

New prostate cancer therapy investigated at VUMC

Thursday, September 22nd, 2016

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D., MPH, professor and chair of Urologic Surgery, and Sandeep Arora, […]

VICC treats first patient in Tennessee with novel cellular immunotherapy

Monday, February 29th, 2016

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]

Study seeks to ease ‘chemobrain’ for cancer patients

Monday, August 24th, 2015

Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment. And as the survival rates for breast cancer increase, so do these issues associated with chemotherapy. Paul Newhouse, M.D., professor of Psychiatry and Jim Turner Professor of Cognitive Disorders, and graduate student Jennifer Vega in Vanderbilt University […]